These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 19552748

  • 21. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
    Uno T, Shimizu M, Sugawara K, Tateishi T.
    Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
    [Abstract] [Full Text] [Related]

  • 22. Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.
    Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, Penzak SR.
    J Clin Pharmacol; 2012 Jun; 52(6):932-9. PubMed ID: 21646440
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of first-pass cytochrome P4503A (CYP3A) and P-glycoprotein activities using alfentanil and fexofenadine in combination.
    Kharasch ED, Walker A, Hoffer C, Sheffels P.
    J Clin Pharmacol; 2005 Jan; 45(1):79-88. PubMed ID: 15601808
    [Abstract] [Full Text] [Related]

  • 24. Influence of drug-transporter polymorphisms on the pharmacokinetics of fexofenadine enantiomers.
    Akamine Y, Miura M, Sunagawa S, Kagaya H, Yasui-Furukori N, Uno T.
    Xenobiotica; 2010 Nov; 40(11):782-9. PubMed ID: 20839930
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The change of pharmacokinetics of fexofenadine enantiomers through the single and simultaneous grapefruit juice ingestion.
    Akamine Y, Miura M, Komori H, Tamai I, Ieiri I, Yasui-Furukori N, Uno T.
    Drug Metab Pharmacokinet; 2015 Oct; 30(5):352-7. PubMed ID: 26213156
    [Abstract] [Full Text] [Related]

  • 27. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration.
    Zhao R, Kalvass JC, Yanni SB, Bridges AS, Pollack GM.
    Drug Metab Dispos; 2009 Mar; 37(3):529-35. PubMed ID: 19114463
    [Abstract] [Full Text] [Related]

  • 28. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
    Ieiri I, Tsunemitsu S, Maeda K, Ando Y, Izumi N, Kimura M, Yamane N, Okuzono T, Morishita M, Kotani N, Kanda E, Deguchi M, Matsuguma K, Matsuki S, Hirota T, Irie S, Kusuhara H, Sugiyama Y.
    J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
    [Abstract] [Full Text] [Related]

  • 29. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.
    Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C.
    Clin Pharmacol Ther; 2008 Oct; 84(4):506-12. PubMed ID: 19238656
    [Abstract] [Full Text] [Related]

  • 30. Oral bioavailability of dabigatran etexilate (Pradaxa(®) ) after co-medication with verapamil in healthy subjects.
    Härtter S, Sennewald R, Nehmiz G, Reilly P.
    Br J Clin Pharmacol; 2013 Apr; 75(4):1053-62. PubMed ID: 22946890
    [Abstract] [Full Text] [Related]

  • 31. Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein.
    Shimizu M, Uno T, Sugawara K, Tateishi T.
    Br J Clin Pharmacol; 2006 Sep; 62(3):372-6. PubMed ID: 16796706
    [Abstract] [Full Text] [Related]

  • 32. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
    Bedada SK, Appani R, Boga PK.
    Drug Dev Ind Pharm; 2017 Jun; 43(6):932-938. PubMed ID: 28102715
    [Abstract] [Full Text] [Related]

  • 33. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
    Choi DH, Chung JH, Choi JS.
    Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
    [Abstract] [Full Text] [Related]

  • 34. Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.
    Turkanovic J, Ward MB, Gerber JP, Milne RW.
    Drug Metab Dispos; 2017 May; 45(5):569-575. PubMed ID: 28188296
    [Abstract] [Full Text] [Related]

  • 35. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A, Kumagai Y, Yamane N, Tozuka Z, Sugiyama Y, Fujita T, Yokota S, Maeda M.
    J Clin Pharm Ther; 2010 Apr; 35(2):169-75. PubMed ID: 20456735
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
    Bedada SK, Yellu NR, Neerati P.
    Pharmacol Rep; 2016 Apr; 68(2):338-43. PubMed ID: 26922536
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. The effects of fexofenadine at steady-state on sleep architecture: a study using polysomnography in healthy Korean volunteers.
    Lee HW, Lee HW, Park DJ, Moon SO, Ahn JH, Kim MJ, Kim SD, Kim JE, Yoon YR.
    Expert Opin Pharmacother; 2008 Jul; 9(10):1655-65. PubMed ID: 18570599
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.